

Anthrax Vaccine Market Forecasts to 2034 – Global Analysis By Vaccine Type (Live Attenuated Vaccine, Cell Free PA Vaccine and Other Vaccine Types), Type, Disease Indication, Age Group, Application, End User and By Geography

<https://marketpublishers.com/r/AD36630620D4EN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: AD36630620D4EN

Abstracts

According to Statistics MRC, the Global Anthrax Vaccine Market is accounted for \$15.58 billion in 2026 and is expected to reach \$25.80 billion by 2034 growing at a CAGR of 6.5% during the forecast period. The Anthrax vaccine is a preventive measure designed to protect individuals from anthrax, a potentially serious bacterial infection caused by the bacterium *Bacillus anthracis*. Anthrax can affect humans and other animals, and it can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. The vaccine is primarily developed to safeguard military personnel, laboratory workers, and individuals at high risk of exposure to anthrax spores. The vaccine stimulates the immune system to produce antibodies against the protective antigen component of the *Bacillus anthracis* bacterium.

According to an article published in the *Veterinary World Journal* in April 2021, the prevalence of anthrax globally was 28% from 2452 samples through the fixed effects model. The random effects model's continent-by-subgroup study showed that the pooled prevalence of anthrax was highest in Africa (29%) and lowest in North America (21%).

Market Dynamics:

Driver:

Increase in prevalence of anthrax

The market has witnessed a notable surge in prevalence, reflecting a growing concern for anthrax-related risks. This upswing has heightened demand for effective vaccines, prompting advancements in research and development. The increasing prevalence of anthrax underscores the imperative for comprehensive vaccination strategies, driving market growth and innovation. However, increasing awareness and education about anthrax vaccines is paramount for public health is the factor propelling the growth of the market.

Restraint:

Side effects and safety concerns

The anthrax vaccine, while effective in preventing anthrax, may cause mild to moderate side effects such as pain, swelling, or redness at the injection site. Some individuals may experience fever, muscle aches, or fatigue. Severe allergic reactions are rare but possible. Safety concerns include reports of adverse events, though the overall risk-benefit profile supports its use for those at high risk of anthrax exposure. These are the factors hampering the growth of the market.

Opportunity:

Technological advancements

The market has witnessed significant technological advancements, with the development of next-generation vaccines incorporating innovative delivery systems and adjuvant to enhance efficacy and safety. Advanced biotechnological methods, such as recombinant DNA technology, have been employed to produce more effective and scalable vaccines. Additionally, advancements in formulation and storage technologies contribute to improved stability and ease of distribution.

Threat:

High manufacturing costs

The complex production process, stringent quality control measures, and the need for specialized facilities contribute to elevated expenses. These high manufacturing costs not only impact the affordability of the vaccine but also pose challenges for market accessibility and widespread distribution, limiting its availability to a broader population.

Addressing these cost-related barriers is crucial for enhancing the affordability and accessibility of anthrax vaccines. These are the factors hindering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic has indirectly impacted the market, with shifts in healthcare priorities and resources. Attention and funding diverted to combat the pandemic may have slowed Anthrax vaccine research and development. Additionally, disruptions in supply chains and healthcare systems could affect manufacturing and distribution. However, the heightened focus on public health and biodefense may underscore the importance of anthrax vaccines, potentially leading to increased awareness and investment in the post-pandemic landscape.

The live attenuated vaccine segment is expected to be the largest during the forecast period

The live attenuated vaccine segment is expected to be the largest during the forecast period. Live attenuated vaccines for anthrax have gained prominence in the market, offering a promising approach to immunization. Leveraging weakened forms of the anthrax bacterium, these vaccines stimulate a robust immune response without causing the disease. The market for anthrax vaccines is witnessing a notable surge in demand for live attenuated options due to their efficacy in conferring long-lasting immunity.

The pharmacies segment is expected to have the highest CAGR during the forecast period

The pharmacies segment is expected to have the highest CAGR during the forecast period. These establishments serve as distribution points for anthrax vaccines, ensuring that individuals and healthcare providers can easily procure the necessary doses. Pharmacies also contribute to public health by offering information and guidance on vaccination schedules, potential side effects, and proper administration. Their involvement in the Anthrax Vaccine market enhances overall vaccine availability and promotes community protection against this serious infectious disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The region's robust healthcare infrastructure and rising awareness regarding

bioterrorism threats contribute to market expansion. Key market players are actively engaged in research and development to enhance vaccine efficacy, fostering market competitiveness. Additionally, strategic collaborations between pharmaceutical companies and government bodies further propel market dynamics, ensuring a steady surge in demand for anthrax vaccines.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Government initiatives promoting vaccination, coupled with advancements in healthcare infrastructure, contribute to market expansion. Key players in the region are focusing on research and development to enhance vaccine efficacy. The growing emphasis on public health measures and preparedness against bioterrorism incidents further propels the demand for anthrax vaccines in the region.

Key players in the market

Some of the key players in Anthrax Vaccine market include AstraZeneca, BioNTech SE, Colondo Serum Company, Emergent Bio Solutions, Merck & Co., Inc, Moderna Inc., Pfizer Inc, Proton Biopharma Ltd, Sanofi, Seqirus, Serum Institute of India Pvt. Ltd and ICON plc.

Key Developments:

In October 2022, ICON plc was selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is currently under clinical trial evaluation.

In June 2022, Emergent BioSolutions Inc. was granted review acceptance of the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) from the US FDA. AV7909 is evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to *Bacillus anthracis* in adults (age group 18 @ @- @ @65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

Vaccine Types Covered:

Live Attenuated Vaccine

Cell Free PA Vaccine

Other Vaccine Types

Types Covered:

Subunit Vaccines

Viral Vector Vaccines

Other Types

Disease Indications Covered:

Viral Disease

Bacterial Vaccine

Other Disease Indications

Age Groups Covered:

Adult

Pediatric

Applications Covered:

Human Use

Animal Use

Other Applications

End Users Covered:

Pharmacies

Hospitals

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032

and 2034

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ANTHRAX VACCINE MARKET, BY VACCINE TYPE

- 5.1 Introduction
- 5.2 Live Attenuated Vaccine
- 5.3 Cell Free PA Vaccine
 - 5.3.1 Anthrax Vaccine Absorbed (AVA)
 - 5.3.2 Anthrax Vaccine Precipitated (AVP)
- 5.4 Other Vaccine Types

6 GLOBAL ANTHRAX VACCINE MARKET, BY TYPE

- 6.1 Introduction
- 6.2 Subunit Vaccines
 - 6.2.1 Toxoid Vaccines
 - 6.2.2 Conjugate Vaccines
 - 6.2.3 Recombinant vaccines
- 6.3 Viral Vector Vaccines
- 6.4 Other Types

7 GLOBAL ANTHRAX VACCINE MARKET, BY DISEASE INDICATION

- 7.1 Introduction
- 7.2 Viral Disease
 - 7.2.1 Influenza
 - 7.2.2 Hepatitis
 - 7.2.3 Herpes Zoster
 - 7.2.4 Rotavirus
 - 7.2.5 Other Viral Diseases
- 7.3 Bacterial Vaccine
 - 7.3.1 Pneumococcal Diseases
 - 7.3.2 Meningococcal Diseases
 - 7.3.3 Bacterial Vaccines
- 7.4 Other Disease Indications

8 GLOBAL ANTHRAX VACCINE MARKET, BY AGE GROUP

- 8.1 Introduction
- 8.2 Adult
- 8.3 Pediatric

9 GLOBAL ANTHRAX VACCINE MARKET, BY APPLICATION

- 9.1 Introduction
- 9.2 Human Use
- 9.3 Animal Use
- 9.4 Other Applications

10 GLOBAL ANTHRAX VACCINE MARKET, BY END USER

- 10.1 Introduction
- 10.2 Pharmacies
- 10.3 Hospitals
- 10.4 Other End Users

11 GLOBAL ANTHRAX VACCINE MARKET, BY GEOGRAPHY

- 11.1 Introduction
- 11.2 North America
 - 11.2.1 US
 - 11.2.2 Canada
 - 11.2.3 Mexico
- 11.3 Europe
 - 11.3.1 Germany
 - 11.3.2 UK
 - 11.3.3 Italy
 - 11.3.4 France
 - 11.3.5 Spain
 - 11.3.6 Rest of Europe
- 11.4 Asia Pacific
 - 11.4.1 Japan
 - 11.4.2 China
 - 11.4.3 India
 - 11.4.4 Australia
 - 11.4.5 New Zealand
 - 11.4.6 South Korea
 - 11.4.7 Rest of Asia Pacific
- 11.5 South America
 - 11.5.1 Argentina

- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
 - 11.6.1 Saudi Arabia
 - 11.6.2 UAE
 - 11.6.3 Qatar
 - 11.6.4 South Africa
 - 11.6.5 Rest of Middle East & Africa

12 KEY DEVELOPMENTS

- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies

13 COMPANY PROFILING

- 13.1 AstraZeneca
- 13.2 BioNTech SE
- 13.3 Colondo Serum Company
- 13.4 Emergent Bio Solutions
- 13.5 Merck & Co., Inc
- 13.6 Moderna Inc.
- 13.7 Pfizer Inc
- 13.8 Proton Biopharma Ltd
- 13.9 Sanofi
- 13.10 Seqirus
- 13.11 Serum Institute of India Pvt. Ltd
- 13.12 ICON plc

List Of Tables

LIST OF TABLES

- Table 1 Global Anthrax Vaccine Market Outlook, By Region (2023-2034) (\$MN)
- Table 2 Global Anthrax Vaccine Market Outlook, By Vaccine Type (2023-2034) (\$MN)
- Table 3 Global Anthrax Vaccine Market Outlook, By Live Attenuated Vaccine (2023-2034) (\$MN)
- Table 4 Global Anthrax Vaccine Market Outlook, By Cell Free PA Vaccine (2023-2034) (\$MN)
- Table 5 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Absorbed (AVA) (2023-2034) (\$MN)
- Table 6 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Precipitated (AVP) (2023-2034) (\$MN)
- Table 7 Global Anthrax Vaccine Market Outlook, By Other Vaccine Types (2023-2034) (\$MN)
- Table 8 Global Anthrax Vaccine Market Outlook, By Type (2023-2034) (\$MN)
- Table 9 Global Anthrax Vaccine Market Outlook, By Subunit Vaccines (2023-2034) (\$MN)
- Table 10 Global Anthrax Vaccine Market Outlook, By Toxoid Vaccines (2023-2034) (\$MN)
- Table 11 Global Anthrax Vaccine Market Outlook, By Conjugate Vaccines (2023-2034) (\$MN)
- Table 12 Global Anthrax Vaccine Market Outlook, By Recombinant vaccines (2023-2034) (\$MN)
- Table 13 Global Anthrax Vaccine Market Outlook, By Viral Vector Vaccines (2023-2034) (\$MN)
- Table 14 Global Anthrax Vaccine Market Outlook, By Other Types (2023-2034) (\$MN)
- Table 15 Global Anthrax Vaccine Market Outlook, By Disease Indication (2023-2034) (\$MN)
- Table 16 Global Anthrax Vaccine Market Outlook, By Viral Disease (2023-2034) (\$MN)
- Table 17 Global Anthrax Vaccine Market Outlook, By Influenza (2023-2034) (\$MN)
- Table 18 Global Anthrax Vaccine Market Outlook, By Hepatitis (2023-2034) (\$MN)
- Table 19 Global Anthrax Vaccine Market Outlook, By Herpes Zoster (2023-2034) (\$MN)
- Table 20 Global Anthrax Vaccine Market Outlook, By Rotavirus (2023-2034) (\$MN)
- Table 21 Global Anthrax Vaccine Market Outlook, By Other Viral Diseases (2023-2034) (\$MN)
- Table 22 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccine (2023-2034) (\$MN)

Table 23 Global Anthrax Vaccine Market Outlook, By Pneumococcal Diseases (2023-2034) (\$MN)

Table 24 Global Anthrax Vaccine Market Outlook, By Meningococcal Diseases (2023-2034) (\$MN)

Table 25 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccines (2023-2034) (\$MN)

Table 26 Global Anthrax Vaccine Market Outlook, By Other Disease Indications (2023-2034) (\$MN)

Table 27 Global Anthrax Vaccine Market Outlook, By Age Group (2023-2034) (\$MN)

Table 28 Global Anthrax Vaccine Market Outlook, By Adult (2023-2034) (\$MN)

Table 29 Global Anthrax Vaccine Market Outlook, By Pediatric (2023-2034) (\$MN)

Table 30 Global Anthrax Vaccine Market Outlook, By Application (2023-2034) (\$MN)

Table 31 Global Anthrax Vaccine Market Outlook, By Human Use (2023-2034) (\$MN)

Table 32 Global Anthrax Vaccine Market Outlook, By Animal Use (2023-2034) (\$MN)

Table 33 Global Anthrax Vaccine Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 34 Global Anthrax Vaccine Market Outlook, By End User (2023-2034) (\$MN)

Table 35 Global Anthrax Vaccine Market Outlook, By Pharmacies (2023-2034) (\$MN)

Table 36 Global Anthrax Vaccine Market Outlook, By Hospitals (2023-2034) (\$MN)

Table 37 Global Anthrax Vaccine Market Outlook, By Other End Users (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Anthrax Vaccine Market Forecasts to 2034 – Global Analysis By Vaccine Type (Live Attenuated Vaccine, Cell Free PA Vaccine and Other Vaccine Types), Type, Disease Indication, Age Group, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/AD36630620D4EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AD36630620D4EN.html>